Merchant & Gould

An Intellectual Property Law Firm

RECEIVED CENTRAL FAX CENTER

DEC 0 1 2003

3200 IDS Center 80 South Eighth Street Minneapolis, Minnesota 55402-2215 USA TEL 612.332.5300 FAX 612.332.9081 www.merchantgould.com

A Professional Corporation

Fax Transmission

December 1, 2003

TO: Commissioner for Patents

Attn: Examiner Anne L. Holleran

Patent Examining Corps

Facsimile Center Washington, D.C. 20231 OUR REF:

FROM:

11669.113USC1

TELEPHONE:

612.371.5311

Katherine M. Kowalchyk

Total pages, including cover letter: 2

PTO FAX NUMBER 1-703.872,9306

If you do NOT receive all of the pages, please telephone us at 612.371.5204, or fax us at 612.332.9081.

Title of Document Transmitted:

INTERVIEW SUMMARY

Applicant:

VAN BRUGGEN ET AL.

Serial No.:

10/648,816

Filed:

August 26, 2003

Group Art Unit: 1642

Our Ref. No.: 11669.113USC1

Confirmation No.:

5367

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: Matheine M. Kowalchyk
Name: Katherine M. Kowalchyk

Reg. No.: 36,848

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

December 1, 2003

boember 1, 2003

6123329081

T-300 P.002/002 F-598

S/N 10/648,816

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

VAN BRUGGEN ET AL.

Examiner:

A. HOLLERAN

Serial No.:

10/648,816

Group Art Unit:

1642

Filed:

AUGUST 26, 2003

Docket No.:

11669.113USC1

Confirmation No.:

5367

Customer No.:

23552

Title:

VASCULAR ENDOTHELIAL CELL GROWTH FACTOR

ANTAGONISTS AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.6(d);

I hereby certify that this paper is being transmitted by facsimile to the U.S. Payent and Trademark Office on December 1,

2003

INTERVIEW SUMMARY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTERVIEW SUMMARY

Applicants wish to thank Examiner Holleran and Examiner Caputa for the interview conducted on October 28, 2003. During the interview, we discussed pending claims in the parent application Serial No. 09/718,694 and the prior art of record. We also discussed submitting claims directed to methods of reducing cerebral edema due to non-neoplastic disorders or conditions.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903

Minneapolis, Minnesota 55402-0903

(612) 332-5300

Date: Deer. 1, 2003

Katherine M. Kowalchyk

Reg. No. 36,848

23552

ine alkowalance

PATENT THADEMARK OFFE